Electro-Diagnostic Devices Market Analysis & Forecast: 2026-2033
The Electro-Diagnostic Devices Market size is anticipated to grow at a CAGR of 5.4% with USD 1,110 Mn in 2026 and is expected to reach USD 1,610 Mn in 2033. The growth is owing to the rising prevalence of neurological, cardiac, and muscular disorders, along with increasing adoption of advanced diagnostic procedures in hospitals and clinics. The cutting-edge innovations like wireless EEG/ECG systems, AI-powered signal analysis, and portable EMG/NCS devices are enhancing accuracy, patient comfort, as well as real-time monitoring. For example, a national physician survey reported that the median number of electromyography (EMG) procedures performed by neurologists annually in the U.S. ranges between 251 and 500, thereby underscoring the routine clinical use of electro
The electro‑diagnostic devices industry in the United States is being transformed by a clear shift toward portable, wearable, and home‑based technologies. The growth is driven by regulatory support and growing clinical adoption.
The recent activity from the U.S. Food and Drug Administration (FDA) highlights an expanding list of authorized sensor‑based digital health devices, including minimally invasive systems designed for real‑world monitoring outside traditional clinical environments.
Ongoing clinical research, including ClinicalTrials.gov. The usage patterns indicate growth, with mean EMG utilization rising 7.7% among neurologists and 20.7% among physiatrists following Medicare policy updates, thereby highlighting the expanding access to the advanced, technology-enabled testing.
In April 2026, Zeto Inc. received the FDA 510(k) clearance for its New Wave outpatient EEG system. It is specifically tailored for use in clinics and home settings, thereby offering a 21‑electrode portable configuration for broader access to brain activity monitoring.
The electro‑diagnostic devices market is expanding as regulatory agencies increasingly recognize and approve AI‑powered diagnostics. According to the U.S., reflecting rapid adoption of AI/ML technologies in clinical diagnostic tools relevant to electro‑diagnostics like ECG and EEG systems.
According to the FDA listings as of late 2024, a total of 1,016 AI/ML medical device authorizations were recorded. Of these, approximately 14.5 percent incorporate signal) which are fundamental for electro‑diagnostic applications. This demonstrates the growing regulatory recognition and incorporation of AI‑integrated electro‑diagnostic devices in clinical practice.
In January 2026, AliveCor Inc. received the FDA clearance for the next-generation KAI 12L AI powering the Kardia 12L ECG system. The update adds five new cardiac determinations, bringing the total to 39, thereby enhancing the diagnostic capabilities of this handheld 12-lead electrocardiogram (ECG) system with a single-cable design.
|
Current Event |
Description and its Impact |
|
CMS 2026 Medicare Physician Fee Schedule – RPM/RTM Reimbursement Updates
|
|
|
Expansion of Medicare Telehealth & RPM Coverage Policies (CMS policy updates) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
By product type, Electroencephalography (EEG) segment is projected to account for the largest Electro-Diagnostic Devices Market share of 31.2% in 2026. The segment’s growth is owing to its essential role in neurological diagnostics and growing clinical adoption. EEG is widely used for epilepsy, sleep disorders, brain injury monitoring, and comatose patient evaluation, establishing it as a critical non-invasive diagnostic tool.
The World Health Organization’s Global Status Report on Neurology indicates that neurological conditions affect more than one in three people worldwide, thereby highlighting the substantial demand for diagnostic technologies like EEG. According to CDC data the epilepsy affects an estimated 3.4 million individuals with active disease in the U.S. This reinforces the sustained clinical reliance on EEG for diagnosis, patient monitoring, and management.
In September 2025, Natus Medical acquired the remaining minority shares of Holberg EEG and gained full ownership. The acquisition brings Holberg’s autoScore AI model into Natus’s Electro-Diagnostic Devices portfolio, providing automatic and comprehensive EEG interpretation with expert-level accuracy and enabling smarter and more accessible brain health solutions.
To learn more about this report, Request Free Sample
Based on end user, the hospitals & clinics segment is poised to dominate the market and accounts for a considerable 49.2% share in 2026. The segment’s growth is owing to the integration of advanced electro‑diagnostic technologies into routine clinical workflows and favorable regulatory developments that facilitate broader device availability.
According to the official Indian import statistics, the electro medical equipment imports encompassing EEG, EMG, and other diagnostic devices were valued at approximately USD 5.28 billion in FY 2024
In March 2026, Natus Medical received the FDA 510(k) clearance for its Nicolet EEG 5 system, an advanced electroencephalography platform designed for hospital neurology departments and outpatient clinics. It aims at enhancing real‑time brain monitoring capabilities and streamlining workflow efficiency in both inpatient as well as outpatient settings.
Additionally, the U.S. FDA granted Breakthrough Device Designation to Ceribell’s LVO stroke detection and monitoring solution, a point‑of‑care EEG‑based platform aimed at early large vessel occlusion stroke identification in hospital environments, potentially accelerating clinical adoption and investment into acute neurodiagnostic tools.
To learn more about this report, Request Free Sample
North America is set to account for the leading position in the Electro-Diagnostic Devices Market. The region occupies a substantial 38.2% share in 2026. The growth is mainly driven by the region’s high diagnostic volumes across cardiology and neurology, strong hospital-based testing capacity, and rapid FDA review of next-generation EEG, ECG, EMG, and nerve-conduction systems.
CDC data show cardiovascular disease caused 919,032 deaths in the U.S., thereby sustaining the demand for ECG, Holter, stress-test, and electrophysiology monitoring devices. The CDC data show that around 2.9 million adults in the U.S. had active epilepsy in, which keeps EEGs in regular use for diagnosing and monitoring seizures.
In March 2026, Onera B.V. received the FDA 510(k) clearance for its Onera SleepMap system, an automated EEG
The Asia Pacific region is poised to be as the fastest-growing region through 2026-2033. The region’s growth is owing to the rising prevalence of neurological and cardiovascular disorders, increasing hospital infrastructure, and expanding adoption of electro-diagnostic devices such as EEG, ECG, and EMG systems.
According to the Global Burden of Disease study, stroke alone accounted for over 109 million disability-adjusted life years (DALYs) in Asia in 2021, highlighting a growing need for neurological disorder diagnostics. In addition, the NLM data indicate that epilepsy affects an estimated 23 million individuals across the Asia Pacific region, thereby highlighting the sustained demand for EEG and other neurological diagnostic devices.
In July 2025, Emergo Asia Pacific Pty Ltd T/a Emergo Australia received TGA registration for its multichannel electrocardiograph, interpretive, home-use device. The device enables at-home full-lead ECG monitoring and interpretive cardiac assessments.
The United States Electro-Diagnostic Devices Market has seen robust growth. The growth is owing to the increasing prevalence of neurological and cardiac disorders, the rising adoption of telehealth and remote monitoring, and regulatory support for home-use diagnostic devices.
According to the National Health Interview Survey (NHIS), 30.1% of the U.S. adults reported using telemedicine in the past 12 months, thereby demonstrating the sustained uptake of remote diagnostic practices which facilitate ECG and EMG data capture.
In December 2025, HeartBeam, Inc. received the FDA 510(k) clearance for its cable‑free synthesized 12-lead ECG system. It allows for the at‑home arrhythmia assessment and full-lead electro‑diagnostic monitoring beyond basic consumer wearable systems.
The Electro-Diagnostic Devices Market in China is influenced by the rising hospital utilization, faster outpatient diagnostics, and wider adoption of ECG, EEG, and EMG systems across neurology, cardiology, rehabilitation, and critical care settings.
In 2024, China’s medical institutions recorded 101.5 billion total diagnosis and treatment visits, up 6.2% year-on-year, creating strong testing volumes for electrophysiology-based diagnosis.
In May 2025, China’s NMPA delivery records listed approval documentation for Cadwell Industries’ electroencephalograph device. This indicates continued demand for advanced EEG systems as hospitals expand neurological assessment, monitoring, and digital diagnostic capacity.
Some of the major key players in Electro-Diagnostic Devices industry are Medtronic, Abbott, Boston Scientific Corporation, Siemens Medical Solutions, Philips Medical Systems, GE Healthcare, Noraxen, Viasys Healthcare, Natus Medical, Cadwell Laboratories Inc, Compumedics Limited, and Nihon Kohden.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,110 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.4% | 2033 Value Projection: | USD 1,610 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic, Abbott, Boston Scientific Corporation, Siemens Medical Solutions, Philips Medical Systems, GE Healthcare, Noraxen, Viasys Healthcare, Natus Medical, Cadwell Laboratories Inc, Compumedics Limited, and Nihon Kohden. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
